AstraZeneca execs 'not worried' after IL-33 drug fails to improve COPD breathing in phase 2

AstraZeneca executives say they are “not worried” that the failure of tozorakimab in a phase 2 chronic obstructive pulmonary disease (COPD) trial will throw their plans for the anti-IL-33 monoclonal antibody off track.